Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Hematologic Malignancies
•
Medical Oncology
•
Leukemia
•
CLL
•
Hematology
•
Ophthalmology
How do you manage ocular hemorrhages while on acalabrutinib for CLL?
Related Questions
How do you manage persistent cytopenias after FCR chemotherapy for treatment of CLL?
In treatment naive CLL without del(17p)/TP53, will the recent interim analysis of fixed duration acalabrutinib plus venetoclax +/- obinutuzumab vs chemoimmunotherapy in the AMPLIFY trial change your practice?
How does the CLL17 trial presented at ASH 2025 change current practice guidelines?
What induction regimen would you consider for KMT2A-rearranged AML in a young patient with multiple medical co-morbidities who is ineligible for clinical trials?
How do you treat patients with T-cell ALL/T-cell lymphoblastic lymphoma who have pre-existing CKD with a CrCl of 30 mL/min or less?
How do you approach c-KIT mutated, core binding factor (CBF) AML?
What is your approach to management of relapsed/refractory T-cell prolymphocytic leukemia (T-PLL)?
If using the triplet AMPLIFY regimen with ven/acala/obin upfront, what do you then plan to use in 2nd line treatment of CLL?
Is there therapeutic relevance for FLT3-ITD mutation in relapsed APML?
In patients with post-PV myelofibrosis who are ineligible for allogeneic stem cell transplant, how do you approach symptomatic splenomegaly refractory to splenic radiation and ruxolitinib?
